Evidence map›Paper›PMID 41710033›Full record

ArticleISME communications2026

Pseudovibriamide B from marine sponge-associated bacteria acts as a selective antibiotic antidote.

Vitor Lourenzon, Yitao Dai, Mandisa Timba, Subhash Yadav, Gabrielle Mingolelli, Matthew Henke, Detmer Sipkema, Alessandra S Eustáquio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ISME communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vitor LourenzonDepartment of Pharmaceutical Sciences and Center for Biomolecular Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60607, United States.ORCID https://orcid.org/0000-0002-5947-4919
Yitao DaiDepartment of Pharmaceutical Sciences and Center for Biomolecular Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60607, United States.
Mandisa TimbaDepartment of Pharmaceutical Sciences and Center for Biomolecular Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60607, United States.
Subhash YadavLaboratory of Microbiology, Wageningen University, P.O. Box 8033, 6700 EH Wageningen, the Netherlands.
Gabrielle MingolelliDepartment of Pharmaceutical Sciences and Center for Biomolecular Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60607, United States.
Matthew HenkeDepartment of Pharmaceutical Sciences and Center for Biomolecular Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60607, United States.
Detmer SipkemaLaboratory of Microbiology, Wageningen University, P.O. Box 8033, 6700 EH Wageningen, the Netherlands.
Alessandra S EustáquioDepartment of Pharmaceutical Sciences and Center for Biomolecular Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60607, United States.ORCID https://orcid.org/0000-0002-7852-7844

Funding

Marine sponge depsipeptides to minimize antibiotic collateral damageR21AI178347 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI EUSTAQUIO, ALESSANDRA S · 2023 to 2024
$440k
NIAID NIH HHS R21 AI178347
6 · The paper itself

Abstract

Broad-spectrum antibiotics, while effective against pathogens, can disrupt microbiota leading to dysbiosis. In natural systems, where most antibiotic classes were first identified, some collateral damage control may have evolved as a microbiota protection strategy to the production of broad-spectrum antibiotics. In this work, we investigated whether pseudovibriamide B (PB), a depsipeptide produced by the marine sponge isolated bacterium

Indexed as

antibiotic antidotemarine bacteriamarine spongesPseudovibrio

Identifiers

PMID41710033
PMCPMC12911931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.